drugset
drugset / Trial / NCT06546475

A Pilot Trial of Tapering Antipsychotics for Patients in Remitted Psychosis Co-administering With N-Acetylcysteine

NCT06546475 ↗

Phase 4 Not yet recruiting 20 enrolled National Taiwan University Hospital
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The investigators are going to observe if add-on of n-acetylcysteine (NAC) 1200 or 2400 mg/d during tapering of antipsychotics in patients with remitted psychosis can help to reduce the pre-requisite of stabilization to 3 months (compared to the 6 months prerequisite of a previous Guided Antipsychotic Reduction to Minimum Effective Dose (GARMED) trial,) smoothly, without increased risk of relapse or frequency of adverse events compared to the 2-year results of the GARMED trial

Timeline

Start
2024-08-01
Primary completion
2027-07-31
Completion
2027-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject N-acetylcysteine Small molecule 1200 mg —
Subject N-acetylcysteine Small molecule 2400 mg —

Indications

psychotic disorder